These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 15492322)

  • 21. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
    Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
    van der Harst P; Asselbergs FW; Hillege HL; Bakker SJ; Voors AA; van Veldhuisen DJ; van Gilst WH;
    Am J Cardiol; 2007 Nov; 100(10):1548-51. PubMed ID: 17996517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery.
    Rouleau JL; Warnica WJ; Baillot R; Block PJ; Chocron S; Johnstone D; Myers MG; Calciu CD; Dalle-Ave S; Martineau P; Mormont C; van Gilst WH;
    Circulation; 2008 Jan; 117(1):24-31. PubMed ID: 18071079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
    Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A
    AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial.
    Thompson PL; Meredith I; Amerena J; Campbell TJ; Sloman JG; Harris PJ;
    Am Heart J; 2004 Jul; 148(1):e2. PubMed ID: 15215811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
    Boekholdt SM; Agema WR; Peters RJ; Zwinderman AH; van der Wall EE; Reitsma PH; Kastelein JJ; Jukema JW;
    Circulation; 2003 May; 107(19):2416-21. PubMed ID: 12742999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease.
    Tonelli M; Isles C; Craven T; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; West M; Packard C; Curhan GC
    Circulation; 2005 Jul; 112(2):171-8. PubMed ID: 15998677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study).
    Mizuno K; Nakaya N; Ohashi Y; Tajima N; Kushiro T; Teramoto T; Uchiyama S; Nakamura H;
    Circulation; 2008 Jan; 117(4):494-502. PubMed ID: 18172039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective study of pravastatin in the elderly at risk: new hope for older persons.
    Shepherd J
    Am J Geriatr Cardiol; 2004; 13(3 Suppl 1):17-24. PubMed ID: 15133425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study.
    Stewart RA; North FM; Sharples KJ; Simes RJ; Tonkin AM; White HD;
    N Z Med J; 2008 Feb; 121(1269):11-23. PubMed ID: 18278078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.
    Schrader J; Lüders S; Kulschewski A; Hammersen F; Züchner C; Venneklaas U; Schrandt G; Schnieders M; Rangoonwala B; Berger J; Dominiak P; Zidek W;
    J Hypertens; 2006 Mar; 24(3):541-8. PubMed ID: 16467658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
    Knopp RH; d'Emden M; Smilde JG; Pocock SJ
    Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease.
    Solomon SD; Lin J; Solomon CG; Jablonski KA; Rice MM; Steffes M; Domanski M; Hsia J; Gersh BJ; Arnold JM; Rouleau J; Braunwald E; Pfeffer MA;
    Circulation; 2007 Dec; 116(23):2687-93. PubMed ID: 18025537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
    Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Zhou Z; Rahme E; Pilote L
    Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
    Mills EJ; Rachlis B; Wu P; Devereaux PJ; Arora P; Perri D
    J Am Coll Cardiol; 2008 Nov; 52(22):1769-81. PubMed ID: 19022156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study.
    Arnlöv J; Evans JC; Meigs JB; Wang TJ; Fox CS; Levy D; Benjamin EJ; D'Agostino RB; Vasan RS
    Circulation; 2005 Aug; 112(7):969-75. PubMed ID: 16087792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences between statins on clinical endpoints: a population-based cohort study.
    Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC
    Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.